Clinical Trial Update: Ovatio DR and VR Implantable Cardioverter Defibrillators Post-approval Study [Phase 3]

View source ↗

Summary

The update reports the completion of a Phase 3 post-approval study evaluating Ovatio DR and VR Implantable Cardioverter Defibrillators for Sudden Cardiac Death.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sudden Cardiac Death

Snippet

Sponsor: ELA Medical, Inc. | Conditions: Sudden Cardiac Death | Phase 3 | Status: COMPLETED